سعر جليبتوباك 25 مجم 30 قرص 2025

Egyptian alogliptin 25 mg tablets (GAP Gliptopack), a DPP-4 inhibitor for type 2 diabetes.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (not for type 1 diabetes).Population: Adults with type 2 diabetes mellitusDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥4%) include nasopharyngitis, headache, and upper respiratory tract infection.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients with a history of serious hypersensitivity to alogliptin or any NESINA excipient (anaphylaxis, angioedema, severe cutaneous reactions reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Warnings include acute pancreatitis, heart failure risk, serious hypersensitivity, hepatic injury, hypoglycemia when combined with insulin or secretagogues, severe arthralgia, and bullous pemphigoid; discontinue if pancreatitis or serious hypersensitivity is suspected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Insulin or insulin secretagogues (e.g. sulfonylureas)ModerateCoadministration may increase hypoglycemia risk; consider lowering the secretagogue or insulin dose.DailyMed (U.S. National Library of Medicine)

• Limited human data with NESINA are insufficient to determine a drug-associated risk for major birth defects or miscarriage; poorly controlled diabetes in pregnancy carries maternal and fetal risks.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Alogliptin: Alogliptin is an orally administered DPP-4 inhibitor used in type 2 diabetes.